Your browser doesn't support javascript.
loading
Pathological response and predictive role of tumour-infiltrating lymphocytes in HER2-positive early breast cancer treated with neoadjuvant pyrotinib plus trastuzumab and chemotherapy (Panphila): a multicentre phase 2 trial.
Liu, Zhenzhen; Wang, Chengzheng; Chen, Xiuchun; Zhu, Jiujun; Sun, Xianfu; Xia, Qingxin; Lu, Zhenduo; Qiao, Jianghua; Zhou, Yong; Wang, Haixue; Wang, Yi; Yan, Min.
  • Liu Z; Department of Breast Disease, Henan Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, Henan, China. Electronic address: zlyyliuzhenzhen0800@zzu.edu.cn.
  • Wang C; Department of Breast Disease, Henan Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, Henan, China.
  • Chen X; Department of Breast Disease, Henan Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, Henan, China.
  • Zhu J; Department of Breast Disease, Henan Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, Henan, China.
  • Sun X; Department of Breast Disease, Henan Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, Henan, China.
  • Xia Q; Department of Pathology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, Henan, China.
  • Lu Z; Department of Breast Disease, Henan Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, Henan, China.
  • Qiao J; Department of Breast Disease, Henan Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, Henan, China.
  • Zhou Y; Department of Breast Surgery, Xinxiang Central Hospital, Xinxiang 453000, Henan, China.
  • Wang H; Department of Breast Surgery, Anyang Tumour Hospital, Anyang 455000, Henan, China.
  • Wang Y; Department of Pathology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, Henan, China.
  • Yan M; Department of Breast Disease, Henan Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, Henan, China.
Eur J Cancer ; 165: 157-168, 2022 04.
Article en En | MEDLINE | ID: mdl-35235873
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Terapia Neoadyuvante Tipo de estudio: Clinical_trials / Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Terapia Neoadyuvante Tipo de estudio: Clinical_trials / Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Año: 2022 Tipo del documento: Article